Clinical trial VISIOCYT 1
2017-2021
In 2017, VitaDX launched a large multicentric prospective clinical trial, named VisioCyt1, on 1,360 patients recruited from 14 hospitals throughout France: the Foch Hospital, Cochin, CHP Antony, CHU Rennes, CHU Clermont Ferrand, HCL Lyon, Clinique Chataigneraie, CH Toulouse, the Paoli-Calmettes Institute in Marseille, CHU Nancy, CH Nantes, CH Nîmes, CH Besançon, Clinique Beausoleil Montpellier.
The results of this multicentric study, finalized in January 2021, confirmed the effectiveness of the deployed solution with an overall sensitivity of over 81% (much higher than that of conventional urinary cytology with a 45% sensitivity), 66.7% versus 25.4% for low grades and finally, 93.7% versus 61.3% for high grade.
